JPWO2022251484A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022251484A5
JPWO2022251484A5 JP2023572828A JP2023572828A JPWO2022251484A5 JP WO2022251484 A5 JPWO2022251484 A5 JP WO2022251484A5 JP 2023572828 A JP2023572828 A JP 2023572828A JP 2023572828 A JP2023572828 A JP 2023572828A JP WO2022251484 A5 JPWO2022251484 A5 JP WO2022251484A5
Authority
JP
Japan
Prior art keywords
composition
nucleotide
sirna
sense strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521792A (ja
JP2024521792A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031115 external-priority patent/WO2022251484A1/en
Publication of JP2024521792A publication Critical patent/JP2024521792A/ja
Publication of JP2024521792A5 publication Critical patent/JP2024521792A5/ja
Publication of JPWO2022251484A5 publication Critical patent/JPWO2022251484A5/ja
Pending legal-status Critical Current

Links

JP2023572828A 2021-05-26 2022-05-26 補体媒介性疾患の治療法 Pending JP2024521792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193573P 2021-05-26 2021-05-26
US63/193,573 2021-05-26
PCT/US2022/031115 WO2022251484A1 (en) 2021-05-26 2022-05-26 Treatment of complement-mediated disorders

Publications (3)

Publication Number Publication Date
JP2024521792A JP2024521792A (ja) 2024-06-04
JP2024521792A5 JP2024521792A5 (https=) 2025-06-02
JPWO2022251484A5 true JPWO2022251484A5 (https=) 2025-06-02

Family

ID=84229204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572828A Pending JP2024521792A (ja) 2021-05-26 2022-05-26 補体媒介性疾患の治療法

Country Status (4)

Country Link
US (1) US20250002910A1 (https=)
EP (1) EP4346844A4 (https=)
JP (1) JP2024521792A (https=)
WO (1) WO2022251484A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
WO2022226127A1 (en) * 2021-04-20 2022-10-27 Alexion Pharmaceuticals, Inc. Compositions and methods for inhibiting complement component 3 expression
CN120265773A (zh) * 2022-10-14 2025-07-04 美国圣因生物股份有限公司 靶向c3的小干扰rna及其用途
EP4600358A1 (en) * 2023-04-14 2025-08-13 Rigerna Therapeutics (Suzhou) Co., Ltd. Compound for inhibiting c3 gene expression, pharmaceutical composition and use thereof
AU2024312039A1 (en) * 2023-06-21 2026-01-22 Changzhou Hansoh Pharmaceutical Co., Ltd. Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof
CN117050998B (zh) * 2023-08-25 2024-02-09 青岛农业大学 一种miRNA在防治溴氰虫酰胺抗性烟粉虱中的应用
JPWO2025143000A1 (https=) * 2023-12-27 2025-07-03
WO2025168134A1 (zh) * 2024-02-08 2025-08-14 北京安龙生物医药有限公司 靶向补体成分c3基因的寡核苷酸及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019113301A (ru) * 2016-10-17 2020-11-17 Апеллис Фармасьютикалс, Инк. Комбинированная терапия для ингибирования с3
AU2018360697A1 (en) * 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021006029A5 (https=)
JP2023103244A5 (https=)
US7737265B2 (en) RNAi modulation of HIF-1 and therapeutic uses thereof
CA2458806C (en) Antisense oligonucleotide against human ache and uses thereof
JP2024045199A5 (https=)
CN105408481B (zh) SERPINA1 iRNA组合物及其使用方法
JP2021518125A5 (https=)
HK1256683A1 (zh) 甲状腺素运载蛋白(ttr)irna组合物及其治疗或预防ttr相关疾病的使用方法
SI2937418T1 (en) Compounds and procedures for inhibiting the expression of transthyretin
JP2012503493A5 (https=)
AU2010207073B8 (en) Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
JP2009535039A5 (https=)
CN116710107A (zh) 用于治疗或预防SNCA相关的神经退化性疾病的SNCA iRNA组成物及其使用方法
JPWO2022251484A5 (https=)
TW202142690A (zh) 富含白胺酸之重複激酶2(LRRK2)iRNA藥劑組合物及其使用方法
CN118853662A (zh) 一种靶向ANGPTL4的siRNA及其缀合物和用途
KR102798766B1 (ko) HBV 발현을 억제하는 RNAi 제제 및 이의 용도
WO2004002535A1 (en) Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis
EP4665852A1 (en) Modified double stranded rna agents
JPWO2021126734A5 (https=)
JPWO2022218941A5 (https=)
JP2024521907A (ja) ヒト９番染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物及びその使用方法
JPWO2021252649A5 (https=)
JPWO2023034837A5 (https=)
JPWO2022256395A5 (https=)